Coya Therapeutics, INC 10-Q quarterly reports

Coya Therapeutics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing ongoing research and development efforts, increased operating expenses, and a continued net loss, while highlighting the need for future capital.

Coya Therapeutics reports a decrease in R&D expenses and an increase in G&A for Q1 2026, with cash reserves projected to last into the second half of 2027.

Coya Therapeutics reported progress on its lead ALS drug candidate, COYA 302, with FDA IND acceptance and a $4.2 million milestone payment, alongside a post-period $23 million public offering.

Coya Therapeutics reported increased net losses and a significant delay in FDA approval for its COYA 302 ALS treatment IND application, impacting its financial outlook.

Coya Therapeutics' Q1 2025 results show increased R&D spending and a widening net loss, driven by the advancement of COYA 302 and expansion of the investigational pipeline.

Coya Therapeutics reported a net loss of $4.0 million for Q3 2024, while advancing its pipeline and securing additional funding.

Coya Therapeutics reports a net loss of $7.9 million for the first six months of 2024, while advancing its pipeline and securing additional funding.

Coya Therapeutics reported a net loss of $5.1 million for the first quarter of 2024, while advancing its pipeline and preparing for an IND filing for COYA 302.